Cargando…

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin‐metformin combination in newly diagnosed Type 2 diabetes

AIM: To assess the long‐term clinical benefits of early combination treatment with vildagliptin‐metformin vs. standard‐of‐care, metformin monotherapy in the ongoing VERIFY study. METHODS: We randomized 2001 participants with multi‐ethnic background, aged 18–70 years, having HbA(1c) levels 48–58 mmol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthews, D. R., Paldánius, P. M., Proot, P., Foley, J. E., Stumvoll, M., Del Prato, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594102/ https://www.ncbi.nlm.nih.gov/pubmed/30576013 http://dx.doi.org/10.1111/dme.13886

Ejemplares similares

Research: Treatment Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trial
por: Del Prato, S, et al.
Publicado: (2014)

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM
por: Matthews, David R., et al.
Publicado: (2019)

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
por: Matthews, David, et al.
Publicado: (2020)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Yoo, Soon-Jib, et al.
Publicado: (2021)

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study
por: Vencio, Sérgio, et al.
Publicado: (2021)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
por: Schweizer, Anja, et al.
Publicado: (2012)

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
por: Kozlovski, Plamen, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
por: Ji, Linong, et al.
Publicado: (2020)

Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin
por: Al Omari, Mousa, et al.
Publicado: (2016)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients
por: Elbere, Ilze, et al.
Publicado: (2020)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Defining and Verifying Durable Opacity: Correctness for Persistent Software Transactional Memory
por: Bila, Eleni, et al.
Publicado: (2020)

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control
por: Saligram, Shreyas, et al.
Publicado: (2012)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
por: Cakirca, Mustafa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r2mui6h1t6lcnt55tdguirov4r